默沙东
MRK
查看详细走势图
119.350USD
+3.670+3.17%
收盘 03/25, 16:00（美东）报价延迟15分钟
363.06B总市值
16.36市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.17%
5天
+3.00%
1月
-3.70%
6月
+49.81%
今年开始到现在
+13.39%
1年
+29.29%
查看详细走势图
TradingKey 默沙东股票评分
单位: USD 更新时间: 2026-03-24操作建议
默沙东当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名20/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价127.84。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
默沙东评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
49°C
过冷
过热
看好
默沙东亮点
亮点风险
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
利润高增长
公司净利润处于行业前列，最新年度总收入65.01B美元
高分红
公司属于高分红公司，最新股息支付率46.40%
稳定分红
公司5年内连续分红，最新股息支付率46.40%
估值合理
公司最新PE估值15.95，处于3年历史合理位
机构减仓
最新机构持股1.99B股，环比减少2.78%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值51.41K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.02
分析师目标
根据
32
位分析师
买入
评级
127.837
目标均价
+11.96%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
默沙东简介
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
公司代码MRK
公司默沙东
CEODavis (Robert M)
网址https://www.merck.com/
相关品种
